- Internationally recognized leaders in clinical trials for bladder cancer
- Comprehensive, state-of-the-art care for all urologic conditions
- Studying immunotherapy as an effective treatment for advanced bladder cancer
If bladder cancer runs in your family or you're concerned about this disease, you should know this one important fact: This type of cancer is highly treatable when diagnosed in the early stages.
The most common form of bladder cancer starts in the organ's innermost tissue layer. “A lot of people know about skin cancer because you can see the skin on the outside,” says Toby Chai, MD, professor of urology and of obstetrics, gynecology and reproductive sciences and co-director of the Female Pelvic Medicine & Reconstructive Surgery Program at Yale Medicine Urology. “Bladder cancer is like a melanoma that you can’t see because it starts on the internal skin of the bladder.”
When bladder cancer spreads to nearby organs and lymph nodes, the disease is considered invasive. Surgery, chemotherapy and radiation therapy can all be treatment options, depending on the severity of this cancer.
The physicians and surgeons at Yale Medicine's Urology Department are at the forefront of bladder cancer treatment and research, integrating innovative approaches and the latest research and technology to provide superior patient care. We have recently played a leading role in a research study testing immunotherapy as an effective treatment for advanced bladder cancer. Our caregivers are committed to offering both early and late-stage bladder cancer patients the most advanced diagnostic technologies and treatment strategies available.